Efalizumab

Author： Talamonti Marina Spallone Giulia Di Stefani Alessandro Costanzo Antonio Chimenti Sergio

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.2, 2011-03, pp. : 239-251

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efalizumab

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 6, Iss. 3, 2007-08 ,pp. : 205-210

Bentham Science Publishers

Access to resources Recommend Favorite

Efalizumab for psoriasis?

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 5, 2004-05 ,pp. : 551-554

Informa Healthcare

Access to resources Recommend Favorite

Efalizumab: Erythroderma: case report

Reactions Weekly, Vol. 1, Iss. 1245, 2009-01 ,pp. : 16-17

Adis International

Access to resources Recommend Favorite

Efalizumab: Candidiasis: case report

Reactions Weekly, Vol. 1, Iss. 1226, 2008-01 ,pp. : 10-11

Adis International

Access to resources Recommend Favorite

Efalizumab: Pancytopenia: case report

Reactions Weekly, Vol. 1, Iss. 1211, 2008-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite